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                       INTRODUCTION 
          stricture disease of urethra  is always a challenge for almost  all 
practicing  urologists.   Treatment   optins  available  such as  dilatation, 
DVIU ,  placement of stent, single or   various stages of  urethroplasty. 
        Management by endoscopy  is  routinely  done  first  for short bulbar 
urethral strictures  before  other modality of treatment.The reported success 
rate of single DVIU is 20 to 60 %. DVIU  don’t produce  epithelial 
approximation  but it separates scarred epithelium so ,wound heals by 
secondry intention. If wound  contraction takes place before  full 
epithelialisation, it significantly narrows lumen  and result in recurrence. 
       Injection  of  steroid  triamcinalone  intralesionally following internal 
urethrotomy  , decrease   formation  of scar by enhancing endogenous 
production of collagenase   and obviates scar formation. In our  study we 
analysed the outcome of  injection  of steroid (triamcinalone)& urethral 
stricture recurrence after DVIU. We analysed time   duration  between VIU  
and urethral stricture disease recurrence. 
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REVIEW OF LITERATURE 
Anatomy:                                                          
Parts of male urethra;              
1. Anterior urethra 
2. Posterior urethra 
Parts of anterior urethra 
-fossa navicularis 
-penile urethra 
-bulbar urethra 
Parts of posterior urethra 
-membranous urethra 
-prostatic urethra 
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    The corpus spongiosum, spongy tissue lies in ventral aspect of corpora 
cavernosa and it surrounds the urethra.  Tunica albuginea of the corpus 
spongiosum  has thinner tunica albuginea, decreased amount erectile tissue  
comparing  to  corpora cavernosa layer of tunica.  
Tough Bucks’ fascia immediately surrounds the tunica albuginea.  On 
dorsal aspect of bucks fascia contains  
1. Deep dorsal vein 
2. Paired dorsal arteries 
3. Br.  dorsal nerves. 
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On ventral aspect, of corpora cavernosa bucks fascia divides and 
surrounds the corpus spongiosum.  Fascia of buck  joins   glans penis distally. 
Proximally at pubis ischium and inferior fascia of the perineal membrane. 
Anterior urethra extends from inferior fascia of urogenital diaphragm to 
external uretral  meatus of penis. 
Within  the spongy erectile tissue of  glans penis is the  Fossa 
navicularis . distal to the attachment of ischiocavernous musculature ,there 
lies penile urethra  but is surrounded by corpus spongiosum. 
The bulbous urethra is covered by the ischiocavernous musculature , 
surrounded by bulbous spongiosus & corpus spongiosus. 
 
Lining epithelium of male urethra: 
 Prostatic urethra- transitional cell epithelium 
 Membranous, bulbar, penile urethra- stratified or pseudo stratified 
columnar 
 Fossa navicularis-  stratified squamous epithelium. 
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Histology  
 Urethra formed by three layers 
1. Mucosal layer. 
2. Sub mucosal layer. 
3. Muscular coat layer. 
I. Mucosal layer: 
As previously mentioned various parts of urethra lined by various type 
of mucosal lining. 
II. Sub mucosal layer: 
It extends throughout the length of the urethra. It has a rich vascular 
and erectile tissues  
 
III. Muscular coat: 
Muscular coat of prostatic and membranous urethra is a downward 
continuation of detrusor muscle layer of bladder.It is innervated by 
sympathetic nerve fibers. The sphincter urethra was formed by the striated 
muscle layer. It is surrounds the membranous urethra. 
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ARTERIAL SUPPLY: 
Blood supply to deeper structures of anterior Urethra  is from common 
penile artery. It is a continuation of internal pudendal artery. It gives two 
branches1) perineal artery 2) posterior scrotal artery, after that  named as 
common penile artery.  Below  the inferior pubic ramus ,on its medial margin 
it continues. 
 
At the bulb of urethra ,  it divides and gives off  3 branches  
1. Bulbourethral artery 
2. Dorsal artery 
3.Cavernosal artery 
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                   ARTERIAL SUPPLY OF URETHRA 
 
 
Bulbourethral artery ,a short artery which pierce perineal membrane to 
enter bulbous spongiosus. It supplies urethra, glans and spongiosum. 
 On dorsal aspect of penis is dorsal artery, which  related medially to 
deep dorsal vein  and lies dorsal nerves laterally  . It was uncoiled when the 
penis was erect. It gives off 3-10 circumflex branches. It accompanies the 
circumflex vein laterally.  terminally on the glans is the branches arborize . 
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There is  dual blood supply for corpus spongiosum. Proximally 
supplied by bulbar and circumcavernosal arteries ,distally by  arborizations of 
dorsal penile artery. 
Based on recent ultrasound studies , the urethral arteries are not 
typically located at 3 or 9 o clock positions(1). Urethral arteries have a 
variable position and location varies  with equal distribution  around the clock 
among patients. Thus urethrotomy location  is not a matter, as it not too deep 
into the spongiosum.  
 
 
Stricture disease 
Etiology 
Basically the involving the anterior urethra is caused by 
1. Inflammatory disease of corpus spongiosum like Balanitis Xerotica 
obliterans (BXO), post gonococcal strictures. 
2. Ischemia-common in patients after urological endoscopic procedures, 
patients with cardiovascular disease. 
3. Traumatic scarring after blunt perineal trauma. 
4. Hypospadias failure. 
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5. Congenital anomalies of the mucosal membrane, usually in the bulbar 
urethra with the corpus spongiosum not involved. 
      In industrialized countries stricture urethra occur due to blunt 
external perineal trauma(eg. Straddle injury) or instrumentation. In 
underdeveloped countries, majority  are inflammatory and commonly 
seen in the bulbar and penile urethra. 
 
       analysis of the literature shows that more strictures are due to 
iatrogenic(33%),idiopathic(33%) and few are becauseof, trauma(19%) 
and inflammation(15%).(5)  
      strictures of the bulb  are  commonly seen(44% to 67%), followed 
by  pendulous urethral strictures in 12% to 39%,combined in 6% to 
28%, meatus or submeatal(0% to 23%),membranous (0 to 20%), and 
prostatic(0% to 4%).(6) 
Pathogenesis  
                       Usually  stricture is a fibrotic reaction, 
with varying gradesof fibrosis  of spongiosum, that cause  tissue  of poorly 
compliance and caliber of urethra narrows . The normal urethra is  covered  
of  pseudostratified columnar epithelium. Below the basement membrane  of 
corpus spongiosum is rich in vascular sinusoids 
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and smooth muscle. The connective tissue has fibroblast and an ECM that has 
collagen, , elastic fibers and glycoproteins.  histologic changes mainly seen  in 
the connective tissue.  Due to damage of epithelial and fibrosis of corpus 
spongiosum stricture results  . 
 
      Scott and Foote(2)stated that  after  trauma  the ulcerated epithelium  
covered by   columnar epithelium which stratified . The  myofibroblasts and 
giant  cellsinfiltration   produce collagen forming fibrosis. 
 
   Singh and Blandy(3)in their  study  found  increase in total amount of 
collagen leads to dense fibrotic stricture with decreased elasticity. 
 
    Baskin (4)found that  not the amount of collagen but change in subtype of 
collagen (increase in type III collagen) result in decreased elasticity and 
compliance of urethra. 
 
    In  traumatic strictures  ,dense scar with decreased elastic fibres seen. 
 
          When most stricture were gonococcal in origin it was nonetheless clear 
that a stricture did not necessarily follow an attack of gonorrhoea, and when it 
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did the time lag could be considerable. Thus an episode of infection or trauma 
is not necessarily a direct cause of stricture. 
         Chambers et al. stated  that first seen  change in stricture of urethral 
disease due to  a change in  feature of lining epithelium of urethra from a 
pseudo-stratified type  to a   columnar epithelium . It has no waterproofing 
quality which seen in  the pseudo-stratified type. So urine  extravasation  
causing   fibrosis. 
 
         Some loss of  lining epithelium is an  important cause leading to 
stricture development.  Exposure of   vascular spaces of corpus spongiosa to 
turine  leads in superficial spongiothrombosis which develops to a 
spongoifibrosis.  Few parts of a  lining epithelium  usually lead  in narrowing 
of  urethral lumen while  healing. when margins  of remaining epithelium are 
approximated during void pressure so that clefts of unepithelialized  areas 
which  heal by adhesion as well as bridging.   
                  During  urine voiding opens  clefts, and this repeated process– 
combined with relatively slow  proliferation-leads to gradual increase in 
underlying spongiothrombosis and later spongiofibrosis  and  formation Of 
stricture. 
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      Singh and Blandy explained why inflammatory stricture  seen commonly 
middle-bulbar & distal part of penile segment urethra ,because that most 
paraurethral glands  are more  in those areas.  the corpus spongiosum fibrosis 
occurs first, caused  directly by the extravasating urine into epithelium of 
urethra or  by involving gland of urethra in some  at specific sites, and 
extending further to into the spongiosum. Once started, fibrosis of corpus 
spongiosum delvelop to narrow of the  lumen and  associated infection in to 
this,  cause  formation of small abscess within the  glands, which  lead  to  
thick fibrosis  and  to peri-urethral extension . 
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Urethra  lined  by  waterproof  pseudo stratified columnar epithelium 
               ↓ 
                           Leaky columnar epithelium  
                                                     ↓      
                             Extravasation of urine and spongiofibrosis   
                                                    ↓ 
                                   Constriction of urethral lumen  
                                                   ↓ 
                                    Micro abscess in urethral glands 
↓ 
                                   Periurethral extension of inflammation →  More severe 
stricture 
Spongiofibrosis  
  The surgical significance of established urethral spongiofibrosis 
is it high predisposition to progress to stricture formation when it is 
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inappropriately used in surgical repair. Thus it is the overall extent of the 
spongiofibrosis associated with a stricture and not simply the length of 
stricture itself-that should properly determine both the type and extent of an 
urethral repair required to achieve satisfactory long-term resolution. If the 
longitudinal extent of the urethral repair is limited only to the length that is 
actually strictured, as opposed to the length of the Spongiofibrotic 
abnormality, it commonly results in restenosis. 
  Severe Spongiofibrosis changes are often palpable and they are 
generally apparent urethrographically by a scarred reduction in the caliber of 
the urethral lumen and by the excavation of the ducts of the glands of the 
Littre and Cowper. Endoscopically spongiofibrotic urethra has a whitish 
colour-quite distinct from the normal urethra that is pink because underlying 
vascular Spongy tissue is seen through the translucent covering of the 
urothelium. However preoperative evaluation even by the Sonourethrogram 
offers only a guide line- the critical extend of the surgically significant 
Spongiofibrotic gray urethral abnormality may not be apparent until it can be 
accurately determine by the direct inspection at the time of  operation when 
the urethra has been opened by the incision extending into truly pink urethra 
proximally and distally –when it is revealed by a well-defined thin layer of 
sub epithelial fibrosis  that is clearly distinguishable. 
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 With further narrowing of the  lumen and if  obstruction of outflow 
develops, secondary changes in the lower urinary tract seen, and also upper 
urinary tract. this obstruction  a predispose to recurrent UTI and secondary 
infection of prostate and epididymis are  common .if <50 yrs Upper tract 
complications are few . 
     Retrograde urethrography  - used  for evaluation of the  urethra from the 
meatus to the proximal bulb portion. The VCUG   assess  posterior urethra. 
 
Figure 1. RUG  showing stricture bulbar urethra 
 
Stricture characteristics 
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       Strictures caused by instrumentation tend to occur at the membranous 
segment and penoscrotal junction. They are  short and smooth type 
.Traumatic stricture are  short,focal, and smooth  seen in the bulbar urethra.  
strictures of infectious cause which  are irregular ,longer , multiple and 
involve bulbar and penile urethra. 
 
       Sonourethrography is another modality used to image  urethra .It has 
high accuracy in determining   length of bulbar urethral stricture and degree 
of spongiofibrosis .sites of  fibrosis around urethra seen as hyperechoic. 
MRI is useful in evaluation of posterior urethal trauma and periurethral soft 
tissue.Strictures become symptomatic  a lumen size below 16F. 
STRICTURE CLASSIFICATION 
According to Devine (7)  1983, who proposed a classification based  on extent 
of fibrosis of corpus spongiosa .Jordan and devine  framed an algorithm  for 
management with types of surgery or urethrotomy on  basis of stage of 
stricture. 
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In 1988 ,McAninch proposed urethral stricture staging system based 
on sonographic appearance (fig.6.2) 
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PHARMACOLOGY OF TRIAMCINALONE 
The chemical name for triamcinolone acetonide is 9-Fluoro-11β,16,17,21-
tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. Its 
structural formula is  
It is available  in white to cream-colored,  powder having slight odor  but it is 
insoluble on dissolving in  water and but so nicely  in alcohol. 
Kenalog®-40 Injection (triamcinolone acetonide injectable suspension, USP) 
is a synthetic glucocorticoid corticosteroid  having  anti-inflammatory  
property .Every mL of the sterile aqueous suspension  gave 40 mg 
triamcinolone acetonide, along sodium chloride because of  isotonicity, 
0.99% (w/v) benzyl alcohol  which act as preservative, 0.75% 
carboxymethylcellulose sodium, and 0.04% polysorbate 80.  to  correct  pH to 
5.0-7.5Sodium hydroxide or hydrochloric acid is present.  During 
productione,  nitrogen replaces  air which  inside  the container 
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Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) 
has an extended duration of effect which may be  used  for a long  a period of 
several weeks. Giving  the single intramuscular injection   , 60 mg to 100 mg  
triamcinolone acetonide, within 24 to 48 hours suppression of adrenal gland 
forms.and  but recovers   usually in 30 to 40 days. 
             
  Hebert(8  initially used  the Local corticosteroid  (triamcinalone) injection 
after internal urethrotomy). by  reducing collagen levels   and 
glycosaminoglycan formation  and production of inflammatory mediators 
.steroids work.(9) 
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MANAGEMENT OF  ANTERIOR URETHRAL STRICTURES 
      The minimally invasive treatment routinely  used for  managing strictures 
are dilation   ,direct vision internal urethrotomy(DVIU). 
 
DIRECT VISION INTERNAL URETHROTOMY 
 
The  overall success rate of  DVIU ranges from 66% to 90%(6)  . it decreases 
drastically  on  follow up for  long periods. 
 In  already  treated, more than(>2cm), multiple strictures, penile  than  bulbar 
strictures and patients with perioperative infections recurrence of stricture is 
high. 
 
The main indications for dilation or DVIU are single site, <2cm strictures of 
bulbar site, without   changes of inflammation and no previous treatment. 
Specific contraindications to  OIU are active infections, bleeding diathesis, 
suspicious of urethral malignancy.  
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Figure 2.Sachse  urethrotome 
TECHNIQUE: 
   DVIU can be done with cold knife or  laser. Cold knife internal urethrotomy  
is done using sachse urethrotome  with 0 or 12 degree telescope .  Incision 
done at 12 o, clock  position and further incision until full thickness of 
stricture  divided upto proximal normal urethra. Enter bladder and perform 
thorough cystoscopy.  Bladder catheterised with 16fr foley. 
Some  do  multiple incisions close together radially of full  thickness of the 
stricture. However recurrence after multiple incisions  don’t vary significantly 
than  single incision  technique. 
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 Different type of lasers are used for performing  DVIU   like Ho:YAG 
laser,Nd: YAG  Laser, KTP laser.  
Complications: 
 Pyrexia(5%),septicemia2%,extravasation 3%, bleeding  
3%,retention2%, 
 Erectile dysfunction-2-11%(10) 
 High flow priapism or a urethral  internal pudendal artery fistula (11-13)     
     
DILATION 
      Dilatation of urethra  by  metal sounds or bougies,  catheters of increasing 
size, filiform and followers ,amplatz dilators or an inflatable balloon.The aim 
of dilation is to stretch the scar tissue without producing more scarring. It is 
usually necessary to dilate  to 20Fr / 24 Fr. 
Stormont and associates reported a success rate at 3yr is 65% for the 
treatment by dilation and DVIU has 68%   success rate, that both modes are 
equally effective for initial management of  strictures of bulbar which are 
short.(14) 
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Most studies have reported that,  recurrence  after DVIU  , it occurs early  
after the procedure, in about 3 to 9 months(15,16,17,18).The most important 
parameter determines  recurrence is duration of follow up. 
Pansadoro and Emiliozzi (19) noted stricture recurrence within 12 mon. after 
DVIU in 56%  recurres in <12 months,  26% at  12-24 months, at 24–36 
months its  8%, during 36–60 months about  7%, and > 60months with  6% 
rate .Steemkamp and associates(20)  found that after dilation or DVIU the risk 
of recurrence of strict. was  high at 6 months and after 12 months it is less. 
RISK FACTORS FOR RECURRENCE: 
1. Etiology 
2. Already  treated stricture 
3. Periurethral scarring 
4. Length of the stricture 
5. Caliber or diameter of the stricture 
6. Number of strictures 
7. Perioperative infections 
PREVENTION OF RECURRENCE 
1. Hydraulic self –dilation 
Done  by  patient, who compress the urethra on& offduring  voiding  
which cause  urethra dilatation. 
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2. Clean intermittent self  catheterization 
Twice a week  for 1 month ,then once weekly, or once daily for 1 
wk,then once weekly or once monthly(21,22). Bodker and associates 
reported need for long term or life time   CIC after DVIU  .(21) 
3. Clinic dilation 
Start  10 days after  urethrotomy, once aweek for 1 month, once at 3 
months and 6 months, later once a year(Tunc and associates). 
4. Steroids 
Intralesional injection of steroid, weekly intra urethral instillation of 
steroid jelly.(23) 
5. Botulinum toxin 
    Injection of botulinum toxin type A following internal urethrotomy 
decreased scar formation (kehra et al)(24) 
 
6. Mitomycin C 
Mitomycin C  inhibits fibroblast proliferation  and prevents scar 
formation. 
7. Brachytherapy 
   Endourethral brachytherapy with 192 Iridium is a safe method to 
reduce restructure rate.(25) 
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8. Injection of captopril  
 
     Holm- Nielson and collegues reported recurrence rates from 50% 
to75% during a 2year follow up period after internal urethrotomy.(26) 
Hardec and coworkers reported that steroid injection decreased 
recurrence rate from 19.4% to 4.3%(27) 
 
             In a recent randomized, placebo-controlled trial, Hosseini and    
        colleagues    injected  triamcinolone  for seventy  patients who are doing   
        CIC  after internal urethrotomy. They started   patients on a urethral               
catheterization program and  used triamcinolone  as  lubrication. Thirty 
patients had inj. Of   triamcinolone (experimental group) and 34 patients were 
using  waterbased jelly injections (control group). Recurrence  in both group   
were30%(experiment) and 44%, respectively.(28) 
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                                    AIM OF THE STUDY 
 
1. To study  the effect of triamcinalone acetate injected intralesionally in 
patients  undergoing internal urethrotomy (DVIU) for anterior urethral 
strictures 
2. To collect short term data on the need for self calibration or dilatation  
and other adjuvant procedures in those patients in one year. 
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MATERIALS AND METHODS 
It is a prospective study  conducted in our institution from January2013 to 
February 2014.After receiving ethical committee approval from our 
institution , around  50 patients  with stricture  of urethra  who are 
symptomatic  and presenting at our hospital were selected . 
STUDY CENTRE 
The study was conducted in Govt. Stanley medical college and hospital , 
Chennai -1. 
 
STUDY DESIGN 
This was a prospective experimental study. 50 patients of   stricture  urethra 
who are symptomatic ,presenting at our hospital  were segregated into two 
groups 25  in each containing  group.The experimental 
Group(D) were treated by cold knife internal urethrotomy with  intralesional  
triamcinolone  injection  while  the  control  group (C) 
treated with urethrotomy alone. Postoperative results were compared between 
two groups. 
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INCLUSION CRITERIA   
1. Anterior urethral stricture <2cm 
2. Age 18-65 years 
 
 
EXCLUSION CRITERIA 
1. Completely obliterated strictures 
2. Urethral strictures >2cm 
3. Neurogenic bladder 
4. History of systemic or immune disease 
5. Patients already on steroids 
6. Patient refusal 
 
 
Preoperative work up  
 Complete history 
 Physical examination 
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 Examination of genitalia and perineum 
 Urine culture and sensitivity 
 USG  KUB 
 Uroflowmetry 
 Retrograde urethrography 
 
 under general or spinal anesthesia procedure is done. Every  patients  
received intravenous prophylactic antibiotics inj. Cefotaxim 1gm i.v 
preoperatively.Cystoscopy  using  20 fr sheath  and  ureteric catheter  of 5 
fr passed through  stricture portion  into the bladder. Using sachse 
urethrotome and cold knife internal urethrotomy done at 12 o, clock 
position , bladder entered and thorough cystoscopy done. After cold knife 
urethrotomy ,80mg of  injection triamcinalone  (diluted with 6ml of 
distilled water to 8ml) was injected  by   cystoscopic injection needle (5 Fr 
size and 23 G needle size, cook medical Inc,) at 12, 3, 6, 9 o clock position 
2ml at each site. After the procedure  using Foleys catheter of 18  fr   
bladder catheterised for 5 days. Antibiotic was given  till  catheter  was 
removed. 
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        After the procedure patients were   evaluated  based on  history  as 
well as uroflowmetry. The urine cultures were  done  after surgery on the 
second  POD. The patients Who are  positive for  culture  received 
appropriate  antibiotics. AUG  was done  in follow up  period if  the 
patient suffer by  difficulty in voiding symptoms or the PFR was below 
15ml/sec. 
 
Followed  up  regularly  l at 3, 6, 12 months and when present with 
symptoms.if  Any symptoms suspicious for  recurrence were found, such 
as thin stream of urine, AUR, and burning micturition. The treatment  was 
reported successful if   they don’t  complain  any voiding symptoms and 
had a  PFR >15ml/sec for a volume of  urine of atleast 150ml. calibration  
of urethra , urethroscopy  or retrograde urethrogram  was done in case of 
difficulty  to pass urine  or reduction in Qmax  flow.  
    
 
 
 
40 
 
     STATISTICAL ANALYSIS 
Descriptive statistics was done for all data and suitable statistical tests of 
comparison were done. Continuous variables were analysed with the unpaired 
t-test and categorical variables were analysed with the Chi-Square Test with 
Yates correction. Statistical significance was taken as P < 0.05. The data was 
analysed using EpiInfo software (7.1.0.6 version; Center for disease control, 
USA) and Microsoft Excel 2010. 
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                       OBSERVATION AND RESULTS 
Two patients in group D(Triamcinalone group) and  3 patients in Group C 
(Control) were lost to follow up and thererfore they were , excluded from our 
study. Data analysis were done  from reports collected of 23 patients and 22 
patients in triamcinalone (D)and control group(C) who fulfilled the follow up 
period  of 12 months after internal internal urethrotomy. 
There was no complication that could be attributed to triamcinalone injection. 
There were no significant perioperative complicatios related to the procedure. 
We noted that frequency , thin stream of urine and burning micturition  were 
the most common presentation. 
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Age  
 
 
 
 
Age Group D % Group C % 
21 to 30 6 26.09 3 13.64 
31 to 40 5 21.74 7 31.82 
41 to 50 7 30.43 4 18.18 
51 to 60 3 13.04 5 22.73 
61 to 70 2 8.70 2 9.09 
71 to 80 0 0.00 1 4.55 
Total 23 100 22 100 
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Age Group D Group C 
Mean 40.84 46.96 
SD 12.63 12.65 
N 23 22 
P value 0.1118 
  
 
 
 
 In our study majority of the patients are in the age groups 31 to 40 
and 41-50 years 
 The mean age in Group D is 40.84 years compared to 46.96 years in 
Group C. 
 Since the p-value is 0.1118, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no difference between the means. 
 This establishes the fact that in spite of difference in age in each 
studygroup, we are dealing with statistically similar groups in relation 
to age 
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Stricture Location  
 
 
Stricture 
Location Group D % Group C % 
Bulbar 19 82.61 17 77.27 
Penile 4 17.39 5 22.73 
Total 23 100 22 100 
P value 0.2001 
 
 19(82.61%) of the Group D patients had stricture in bulbar urethra 
 17(77.27%) of the Group C patients had stricture in bulbar urethra 
 Since the p-value is 0.2001, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no statistical difference between the 
proportions of study groups in relation to stricture location 
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Recurrence 
as per 
Stricture 
Location 
Group D % Group C % 
Bulbar 4 80.00 9 81.82 
Penile 1 20.00 2 18.18 
Total 5 100 11 100 
P value 0.931 
 
 .4(80%) of the Group D patients with stricture in bulbar urethra had 
recurrence of stricture  
 9(81.82%) of the Group C patients with stricture in bulbar urethra  
had recurrence of stricture after intervention 
 Since the p-value is 0.931, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is nostatistical difference between the 
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proportions of study groups in relation to recurrence as per stricture 
location Stricture Causes  
 
 
Stricture 
Causes Group D % Group C % 
Trauma 10 43.48 11 50.00 
Inflammation 3 13.04 3 13.64 
Idiopathic 10 43.48 8 36.36 
Total 23 100 22 100 
P value 0.248 
 
 10(43.48%) of the Group D patients had stricture due to traumatic 
aetiology 
 11(50%) of the Group C patients had stricture due to traumatic 
aetiology  
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 Since the p-value is 0.248, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is nostatistical difference between the 
proportions of study groups in relation to stricture causes 
 
 
 
Recurrences 
as per 
Stricture 
Causes 
Group D % Group C % 
Trauma 3 60.00 6 54.55 
Inflammation 1 20.00 1 9.09 
Idiopathic 1 20.00 4 36.36 
Total 5 100 11 100 
P value 0.726 
 
 3(60%) of the Group D patients with stricture due to trauma had 
recurrence of stricture after intervention 
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 6(54.55%) of the Group C patients with stricture due to trauma had 
recurrence of stricture after intervention 
 Since the p-value is 0.726, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no statistical difference between the 
proportions of study groups in relation to recurrence as per stricture 
causes Recurrence of Stricture 
 
 
Recurrence 
of Stricture Group D % Group C % 
Recurrence+ 5 21.74 11 50.00 
Recurrence- 18 78.26 11 50.00 
Total 23 100 22 100 
P value 0.048* 
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 5(21.74%) of the Group D patients had recurrence of stricture after 
intervention 
 11(50%) of the Group C patients had recurrence of stricture after 
intervention 
 Since the p-value is 0.048, i.e. lesser than 0.05 (or 5 percent), it can 
be concluded that there is difference between the proportions of study 
groups in relation to recurrence as per stricture causes 
 By conventional criteria the association between the study groups and 
recurrence of  stricture is considered to be statistically significant . 
 In contrast, we can conclude that the cold knife internal 
urethrotomywith intralesional triamcinolone injection Technique is 
superior to the internal  urethrotomy Technique  in terms of  preventing 
recurrence of stricture with an Overall success rate of 78.26 % in Group D and 
11% in Group C 
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Time to Recurrence  
 
 
Stricture 
Causes Group D % Group C % 
1 to 3 0 0 1 9.09 
4 to 6 0 0 5 45.45 
7 to 9 2 40 3 27.27 
10 to 12 3 60 2 18.18 
Total 23 100 22 100 
     
 
Time to Recurrence  
(in months) Group D Group C 
Mean 9.6 7.09 
SD 1.14 2.06 
N 23 22 
P value 0.0.017* 
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 3(60%) of the Group D patients had recurrence of stricture after 
intervention between 10 to 12 months 
 5(45.45%) of the Group C patients had recurrence of stricture after 
intervention between 4 to 6 months 
 The mean Time to Recurrence in Group D is 9.6 months compared to 
7.09 months in Group C. 
 Since the p-value is 0.017, i.e. lesser than 0.05 (or 5 percent), it can 
be concluded that there is difference between the means and 
proportions of study groups in relation to time taken for recurrence of 
stricture after intervention 
 By conventional criteria the association between the study groups and 
time taken for recurrence of  stricture after intervention is considered 
to be statistically significant  
 In contrast, we can conclude that the cold knife internal urethrotomy 
with intralesional triamcinolone injection Technique is superior to the 
plain urethrotomy Technique  in terms of  Time taken for delay in 
recurrence of stricture after intervention 
The time taken for developing recurrence of stricture after intervention 
is 2.51 months delayed in Group D compared to Group C.   
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Stricture Length 
 
 
 
Stricture 
Length  
(in cms) 
Group D % Group C % 
0.1 to 0.5 2 8.70 2 9.09 
0.6 to 1.0 12 52.17 12 54.55 
1.1 to 1.5 9 39.13 7 31.82 
1.6 to 2.0 0 0.00 1 4.55 
Total 23 100 22 100 
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Stricture Length  
(in cms) Group D Group C 
Mean 1.04 1.12 
SD 0.25 0.31 
N 23 22 
P value 0.0.3597 
 
 
 
 12(52.17%) of the Group D patients had stricture length between 0.6 
to 1 cm 
 12(54.55%) of the Group C patients had had stricture length between 
0.6 to 1 cm 
 The mean stricture length in Group D is 1.04cm compared to 1.12cm 
in Group C. 
 Since the p-value is 0.3597, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no difference between the means and 
proportions of study groups in relation to the stricture length 
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Recurrence 
in 
Comparison 
to Stricture 
Length  
Group D % Group C % 
0.1 to 0.5 0 0 0 0 
0.6 to 1.0 1 20 4 36.36 
1.1 to 1.5 4 80 6 54.55 
1.6 to 2.0 0 0 1 9.09 
Total 5 100 11 100 
P value  0.575 
             
            In group D  patients with stricture <1cm had recurrence of 20% and 
patients with 1-2cm stricture had a recurrence of 80% 
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             In group C patients with recurrence with <1cm length of  stricture 
was 36.36% and in stricture 1-2cm recurrence is about 54.55%  
 4(80%) of the Group D patients with stricture length 1.1 to 1.5cm had 
recurrence of stricture  
 6(54.55%) of the Group C patients with stricture length 1.1 to 1.5cm 
had recurrence of stricture  
 Since the p-value is 0.575, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no statistical difference between the 
proportions of study groups in relation to recurrence as per stricture 
length 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Urine Culture 
 
 
Urine 
Culture  
Pre 
Operative 
 
Group D % Group C % 
Culture+ 7 30.43 10 45.45 
Culture- 16 69.57 12 54.55 
Total 23 100 22 100 
P value 0.299 
 7(30.43%) of the Group D patients had Urine culture positive pre 
operatively  
 10(45.45%) of the Group C patients had Urine culture positive pre 
operatively   
 Since the p-value is 0.299, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no statistical difference between the 
proportions of study groups in relation to positive urine culture pre 
operatively  
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Recurrence 
as per Pre 
Operative 
Urine 
Culture 
Group D % Group C % 
Culture+ 2 40 4 36.36 
Culture- 3 60 7 63.64 
Total 5 100 11 100 
P value 0.889 
 
 2(40%) of the Group D patients with Urine culture positive pre 
operatively  had recurrence of stricture after intervention 
 4(36.36%) of the Group C patients with Urine culture positive pre 
operatively  had recurrence of stricture after intervention 
 Since the p-value is 0.889, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no statistical difference between the 
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proportions of study groups in relation to positive urine culture pre 
operatively and recurrence of stricture after intervention 
 
 
 
Urine 
Culture  
Post 
Operative 
 
Group D % Group C % 
Culture+ 5 21.74 8 36.36 
Culture- 18 78.26 14 63.64 
Total 23 100 22 100 
P value 0.279 
 
 5(21.74%) of the Group D patients had Urine culture positive post 
operatively   
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 8(36.36%) of the Group C patients had Urine culture positive post 
operatively   
 Since the p-value is 0.279, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no statistical difference between the 
proportions of study groups in relation to positive urine culture post 
operatively  
 
 
 
Recurrence 
as per Post 
Operative 
Urine 
Culture 
Group D % Group C % 
Culture+ 3 60 6 54.55 
Culture- 2 40 5 45.45 
Total 5 100 11 100 
P value 0.838 
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 3(60%) of the Group D patients with Urine culture positive post 
operatively  had recurrence of stricture after intervention 
 6(54.55%) of the Group C patients with Urine culture positive post 
operatively  had recurrence of stricture after intervention 
 Since the p-value is 0.839, i.e. greater than 0.05 (or 5 percent), it can 
be concluded that there is no statistical difference between the 
proportion of study groups in relation to positive urine culture post 
operatively and recurrence of stricture after intervention 
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Peak 
Flow 
Group D Group C P value 
 Mean SD N Mean SD N  
Baseline 6.24 2.20 23 6.31 1.62 22 0.9037 
Post OP 22.83 2.17 23 22.36 2.59 22 0.5167 
3 
months 
21.09 2.09 23 20.09 3.46 22 0.2531 
6 
months 
19.93 2.17 23 17.27 5.20 22 0.0345* 
12 
months 
17.57 3.95 23 14.68 5.27 22 0.0451* 
 
 
 The mean  peak flow rate at the end of 9 months after intervention in 
Group D is 19.93ml compared to 17.27ml in Group C. 
 Since the p-value is 0.0345, i.e. lesser than 0.05 (or 5 percent), it can 
be concluded that there is difference between the means and 
proportions of study groups in relation to  peak flow rate 9 months 
after intervention 
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 The mean  peak flow rate at the end of 12 months after intervention in 
Group D is 17.57ml compared to 14.68ml in Group C. 
 Since the p-value is 0.0451, i.e. lesser than 0.05 (or 5 percent), it can 
be concluded that there is difference between the means and 
proportions of study groups in relation to  peak flow rate 12 months 
after intervention 
 By conventional criteria the association between the study groups and  
peak flow rate 9 and  12 months after interventionis considered to be 
statistically significant  
 In contrast, we can conclude that the cold knife internal urethrotomy 
with intralesional triamcinolone injection Technique is superior to the 
plain urethrotomy Technique  in terms of    better  peak  flow rate. 
 The peak  flow rate stricture after  9 months after intervention is 2.66 
ml more in Group D compared to Group C 
 The peak  flow rate stricture after  12 months after intervention is 
2.89 ml more in Group D compared to Group C 
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                                        DISCUSSION  
      The incidence of stricture urethra in male is about 0.6%(29). The most 
important complication of treatment of strictures is recurrence.(30).the causes 
for stricture being  trauma, catheterization,instrumentation,chronic 
inflammatory disease like BXO,and sexually transmitted diseases. Most  
sytricture urethra are caused by idiopathic etiology and mostly due to 
unnoticed childhood trauma(31). 
    Cut the stricture and anastamosis end to end  of  has  cure rate of 90-95%. 
But internal urethrotomy is  a simple procedure in treatment of stricture 
disease and is followed as first  treatment modality,though  the success rate is 
33%  by 10 years which  was lower  to urethroplasty  on long  follow up.(32) 
     Internal urethrotomy   act by setting apart  fibrosed  epithelium so that 
while healing  starts  and finished by secondary intention occurs.if 
epithelialization  occurs completely before  contraction of wound,urethrotomy 
will be successful but  when will stricture recurres is if   contraction of wound 
occurs before  completion of epithelialisation   
      If any drug or procedure which delays wound contracture  would result in 
delay appearance of stricture .Triamcinalone  acetonide ,  which has strong  
anti-inflammatory   action  reduce  collagen pdt. and stops fibroblast 
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proliferation at   level of wound tissue.this was the reason why for giving 
intralesional steroid after internal urethrotomy  of my work 
       The follow up period in our study was 12 months from last internal 
urethrotomy. to assessing the success of internal urethrotomy  vs  recurrence 
we have to follow up for long term. Every year success rate decreases by of 
10 to 20 % per year is noted  after DVIU ,which may   continue till   upto five 
year. Following  DVIU recurrence rate of 35% to 60% have been reported 
     Holm -Neilsen and collegues(36)  reported  50% to 75% recurrence 
during a two year follow up. The overall  recurrence rate in our study was for 
(1 year)35.5% , recurrence in control group was 50% which is consistent  
with Holm-Nielsen  and colleagues. The lower recurrence reason  may be due 
to short follow up period in our study. 
          According to Naude et al, (33).  most of the recurrence occurs during 3 
to 12 months after internal urethrotomy. In our study recurrence in the control 
group(C)  was 50% compared to 21.7% in triamcinalone group(D). There was 
significantly decrease in recurrence rate  in group D( Triamcinalone group) 
compared to group C   Recurrence rate between the groups  in our study 
reached   statistically significant  value (p=0.048). 
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       The  mean time to recurrence in group D is 9.6 months compared to 
7.09 months in group C  which reached a statistically significant value 
(p=0.017). 
        Rapp et al (35) in their survey found that for strictures <1cm ,most prefer 
internal urethrotomy and for stricture > 2cm , primary  excision and 
anastamosis is preferred (success rate >95%). In our study ,the mean stricture 
length in group D was 1.04cm, in group C was 1.12 cm , which did not show 
any statistically significant value (p=0.359).  In our study  stricture < 1cm 
showed a recurrence rate of 20% in group D and 36.36% in group C. For 
stricture >1cm recurrence in group  D  80%  and in group C  was 63%. 
Strictures less than 1 cm showed less recurrence rate than strictures between 
1-2cm between the groups.this was in according to Rapp et al study. 
       Shirazi et al (37)used captopril gel after DVIU  with good results,but 
heterogeneity of patients makes  interpretation of their results difficult. 
       Santosh kumar et al (38)reported a success rate of 76%  with 
triamcinalone injection following Ho: YAG laser internal urethrotomy. 
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       Based on etiology , success rates with iatrogenic  cause for stricture  has 
higher success rate than with  post-traumatic or post inflammatory cause.(38)   
In our study,  the etiology of stricture was not  significantly  associated with 
outcome of cold knife internal urethrotomy (p=0.726). The recurrence rate 
was found to be independent of  the age of the patient , duration  of     
symptoms, etiology  of stricture, location of stricture( penile or bulbar). 
       Kamp et al,(34)  in their study  found most of the recurrences  were seen 
in strictures >1.5cm.  In our study  better outcome   in strictures less than 
<1cm ( recurrence -20%)  is in accordance with study  of Rourke and 
Jordan(39) ,found  for strictures <1cm  with minimal spongiofibrosis, have 
better results. 
     Hosseini et al,(40) reported good results  in short strictures<1cm(recurrence 
4.2%), compared to longer ones (recurrence 42.9%). Many studies have 
shown  that  endoscopic procedures  for short strictures have better outcome 
than for longer stricture,with success rate of   85 to 87% for <1 cm 
strictures(38).Our study has a success rate of   80% for stricture <1cm.  
       Stricture  recurrence found to be directly proportional  to length of 
stricture. Pansadoro and Emiliozzi(41)   showed recurrence rate higher for > 
1cm stricture.rate of recurrence is about 51 to 72% in many studies.(42-44)  
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In our study  the recurrence rate for  stricture < 1cm was 20%  and for 
strictures 1-2cm the recurrence rate was 80%.This was in accordance to 
Pansadaro et al study. 
         Urinary tract infection in post op period  found to affect the results in 
our study. Out of 12 patients who had urine culture positivity  , 7 had 
recurrence (58.3%). Of 33 patients with sterile urine, 9 had recurrence 
(27.2%), but did not showed statistically significance between the groups 
(p=0.08) 
         Boccon  Gibod and Le Portz (42)  revealed  length, location, cause of 
stricture and UTI  were factors affecting outcome. 
        The recurrence rate   after DVIU  ranges from 30 to 58%. To reduce the 
recurrence rate  with DVIU, various procedures like urethrotomy  combined 
with hydraulic self dilatation, intra urethral mitomycin C, intraurethral  
captopril gel etc are followed. One such technique is  injection of steroids  
with internal urethrotomy. 
          
              Nabi and Dogra (45)study revealed , use of intralesional steroid and 
Nd:YAG laser in the treatment of traumatic prostatic and supraprostatic 
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strictures. During  mean follow-up of 23 months,all 3 patients were 
asymptomatic and voiding well and were found to have normal results on 
cystoscopy, urethroscopy, and uroflowmetry done at 3 months. 
             Hosseini et al. (46) compared patients undergoing clean intermittent 
catheterization with or without triamcinolone ointment following internal 
urethrotomy. At a follow-up of 12months, recurrence was noted in 30% in the 
triamcinolone group compared with 44% in the other. 
 
  LIMITATIONS OF OUR  STUDY 
 
     The  limitations of our study is small number of patients and short follow 
up period (12 months).  Follow up in our study covered the critical period of 
recurrence usually 18 months as stated by Gucuk et al.(47). 
 
    A  larger , randomized controlled study with longer follow up is required to 
confirm these findings and to establish the efficacy of triamcinalone and cold 
knife internal urethrotomy. 
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                                       CONCLUSION 
 
 From our study   we conclude  that  injection of steroid triamcinalone  
following internal urethrotomy  decrease the recurrence rate of 
stricture as well as delays the time to recurrence when compared to 
internal urethrototmy alone  for the treatment of short segment urethral 
strictures(<2cm). 
 
 To  achieve  curative and  long-term effects, this technique of injection 
of steroid following internal urethrotomy  has  to be conducted  on a 
large group of patients with long duration of follow up and  special 
emphasis on objective verification of the safety and efficacy profile. 
 
 
 Injection of steroid at stricture site  can be considered as safe and 
effective adjuvant  modality  after internal urethrotomy.  
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                                              APPENDIX 
                                               PROFORMA 
 
DOA:   DOS:     UNIT :  
Name of Patient: 
Age:   Sex: M/F   IP No.  
 
Address & Phone No: 
 
History: 
- Straining to void/LUTS symptoms 
- Fever 
- Dysuria 
- H/o Pyuria/Hematuria/Calculuria 
- H/o trauma/Acute Urinary retention/Indwelling catheter 
/instrumentation 
- Diabetes mellitus/Hypertension/Tuberculosis  
- Previous manipulation/Procedure  
- Use of steroids 
- H/o systemic or immune disease  
- DM/HT/TB/BA/IHD 
 
Clinical Examination: 
Pallor/Pedal edema/Fever/Lymphadenopathy 
Pulse:    BP:  
  
CVS:     RS: 
  
P/A 
 
Genitals: 
 
 
 
 
DRE: 
 
Pre OP Investigation: 
CBC 
 
URINE R/E 
RFT 
 
 
URINE C/S 
Uroflowmetry 
Peakflow-  
Mean flow- 
Voided volume /PVR 
USG KUB 
Ascending urethrogram 
 
 
 
 
 
MCU  
 
 
 
 
Cystoscopy   
 
 
HIV/VDRL/HBsAg  
 
 
 
Diagnosis : 
Procedure:  
Post Op: 
General Condition  PR:  BP:  Temperature: 
Investigation: 
Catheter removal after 5 – 7 Days  
Follow up: 
Uroflow After catheter 
removal 
3 Month 6 Month 1 Year 
PF 
MF 
Volume /PVR 
    
AUG 
 
 
 
   
 
 
 
 
 
  
                   ேநாயாளக¶tகான ஆேலாசைன 
சி² நƫ  ேநாயாள  சி²நƫ  கழிt பாைதய  ¯tக  ம² அைட~© , 
ெதா² ேநா கி¯மிக , வப{¢tக ம² 
பலவைகயான  காரணuகளால ஏபகிற¢. அ|த அைட~ப  ஏறவா² 
சி² நƫ வ¯ பாைத  வழியாகேவ அைத கிழி{¢ அ²ைவ சிகிvைச 
ெசயபகிற¢ . இ¯~ப§ அ|த அைட~© மz வர வா~©  உள¢. 
அைத த~பத அ²ைவ சிகிvைசய} ேபா¢ அ|த இட{தில 
{Ƭயாசினேலா}  எ}§ ம¯|¢ ெச´{தினா அ|த அைட~© மz 
வ¯ வா~©  ைறகிற¢ ம² அதனா ஏப ந}ைமக பறிய 
ஒ¯  
ஆவைன ேமெகாz உேள}. இ|த கzகாணtக~பyட ம¯{¢வ 
ஆவ தாuக¶ பதிº ெச¢ தuகள¢ «¸ ஒ{¢ைழ~ைப நமா² 
தuகைள அ}©ட} ேகyெகாகிேற} . 
 
                            ேநாயாளக ஒ~©த  
இ|த ேநா, அதtகான பƬேசாதைன  ம² நட{த~ப ஆைவ பறி 
«¸ைமயாக ம¯{¢வƫ வளtகினாƫ. நா} இ|த ஆவ பuெகtக «¸ 
மன¢ட} சமத ெதƬவகி}ேற} . 
   
                                           
                                             ேநாயாளய} ைகெயா~ப   
 
 
 
  
அ§~©னƫ 
        ெபயƫ                 : 
        த|ைத  ெபயƫ          :    
        «கவƬ               :         
        வய¢                 :     
ெப²நƫ 
ஐயா, 
    நா} ேமெசா}ன «கவƬய வசி{¢ வ¯கிேற}.தேபா¢ .....................................  ெதாழி 
ெச¢ வ¯கிேற}. எனt சி²நƫ கழி~பதி சிரம, அைட~©, அtக கழி{த ேபா}ற 
ெதா|தரவகாக டா}லி ம¯{¢வமைன வ|¢ேள}.   எ}ைன பƬேசாதி{த ம¯{¢வƫ 
எனt சி²நƫ வ¯ பாைதய அைட~© உளதாகº   அத ஆபேரஷ} ெசய ேவzய 
அவசிய{ைத வளtகிறினாƫ. இ|த ேநாைய பறிய ச|ேதககuகைள நா} ேகyக 
வளtகினாƫ .இ|த ஆபேரஷ} த}ைம,பtக ம² ப} வைளºகைள­ ம¯{¢வƫ 
வளtகினாƫ.  
.          இ|த இ|த ஆவனா எனt ெபா¢வாக  சி²நƫ கழிt பாைதய அைட~© 
உளவƫக¶t ய ந}ைமக எனt எ{¢ைரtக~பyடன. இ|த ஆº றி{¢, 
நா} எ¸~பய வனாtக ம² ச|ேதகuக¶t ம¯{¢வƫ வளtகமாக பதிலள{தாƫ. 
இவைற ெதƬ|¢ ெகாzட நா} என¢ ய நிைனºட} இ|த ஆவ பuேகக என¢ 
வ¯~ப{தி}ேபƬ யா¯ைடய நிƫப|த« இலாம எ} ய நிைனºட} இ|த ஆவ 
பuேகக என¢ வ¯~ப{ைத ெதƬவ{¢tெகாகிேற}. இ|த ஆº, எ}§ைடய, ம² 
எ} ேபா}ற ேநாயாளயƫ நல} க¯திேய ெசய~பகிற¢ எ}பைத அறி|ததா இத 
எ}ைன ஆyபட¢கி}ேற}. 
 
இ|த ஆº றி{¢ «¸ வவரuகைள நா} ேகy ெப²ளதா´, எ}§ைடய 
வ¯~ப{தி}ேபƬ பu ெகாவதா´, இ¢ றி{¢ எ|த ற «ைறயyைட­ 
ம¯{¢வƫ மேதா, ஏைனய ம¯{¢வ ஊழியƫக மேதா, ம¯{¢வமைன மேதா எ|த 
நிைலய´ ைவtக மாyேட}. இைதேய எ}§ைடய ஒ~©த ம² ேவzேகா 
கதமாக ஏ²tெகா¶மா² ேகytெகாகிேற}.   
                                                       ேநாயாளய} ைகெயா~ப  
          
சி²நƫ பாைதய ஏப அைட~ப அ²ைவ சிகிvைசய} ெபா¢ 
{Ƭயாசினேலா}  எ}§ ம¯|திைன ெச´{¢வதா ஏப 
வைளºக பறிய ஆº . 
 
ேநாயாளய} ஒ~©த பவ 
ஆராvசி நிைலய                            : அர டா}லி ம¯{¢வமைன, ெச}ைன 600001 
பu ெப²பவƬ} ெபயƫ       :  
பu ெப²பவƬ} ைகெயா~ப : 
பu ெப²பவƫ இதைன (     )  றிtகº 
 
ேமேல றி~பyள ம¯{¢வ ஆவ} வவரuக எனt வளtக~பyட¢.   
எ}§ைடய ச|ேதகuகைள ேகyகº, அதகான த|த  வளtகuகைள  
ெபறº வா~பளtக~பyட¢ . 
 
நா} இ|த ஆவ த}னvைசயாக{தா} பuெப¯கிேர} .எ|த       
காரண{தினாேலா எ|த சyடசிtகக¶t உyபடாம நா} இ|த  
ஆவ இ¯|¢ வலகிtெகாளலா எ}² அறி|¢ ெகாzேட}. 
 
இ|த  ஆº சப|தமாகேவா, இைத சாƫ|த ேம´ ஆº ேம 
ெகா¶ ேபா¢ இ|த ஆவ பuெப² ம¯{¢வƫ எ}§ைடய  
ம¯{¢வ அறிtைககைள பாƫ~பத எ} அ§மதி ேதைவயைல  
என அறி|¢ெகாகிேற}.நா} ஆவ இ¯|¢ வலகிtகிெகாzடா´ இ¢  
ெபா¯|¢ என அறி|ேத}. 
 
இ|த  ஆவ} ¬ல கிைடt தகவகைள­ , பƬேசாதைன  
«ºகைள­, ம² சிகிvைச ெதாடƫபான தகவகைள­ 
 ம¯{¢வƫ ேமெகா¶ ஆவ பய}ப{திtெகாளº அைத 
 பரƬtகº எ} «¸ மன¢ட} சமதிtகிேற}. 
   
 
                   
 
 
இ|த ஆவ பu ெகாள ஒ~©tெகாகிேற}. எனt ெகாtக~பட  
அறிºைரகள} ப நட|¢ ெகாவ¢ட} இ|த ஆைவ ேமெகா¶ 
 ம¯{¢வ அணt உzைம­ட} இ¯~ேப} எ}² உ²தி 
 அளகி}ேற}. எ} உட நல பாதிtக~பyடாேலா அல¢ எதிƫபாராத, 
 வழtதிƫtமாறன ேநாtறி ெத}பyடாேலா உடேன அைத 
 ம¯{¢வ அணt ெத¯வ~ேப} என உ²தி அளtகிேற}. 
 
இ|த ஆவ எனt ர{த, சி²நƫ, எtேர, ேக}, உyபட  
அைன{¢ பƬேசாதைனகைள­ ெச¢ ெகாள நா} «¸  
மன¢ட} சமதிtகிேற}. 
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f-
12m
l,vv200m
l,pv
r-50m
l
yes,6 m
onths
8
yesudoss
70
51772
penile
1
inflam
m
c
IU
N
G
N
G
spc
pF-23m
l,M
F-
9m
l,vv-280m
l
pf-22m
l,m
f-
18m
l,vv-
240m
l,pvr 10m
l
pf-21m
l,m
f-
17m
l,vv-245m
l
pf-20m
l,m
f-
15m
l,vv180m
l,pv
r-10m
l
N
O
9
aranganathan
38
53377
bulbar urethra
1
idiopathic
c
IU
E-coli 
N
G
pf-6m
l,m
f-
4m
l,vv152m
l,pvr
100m
l
PF-24m
l,M
F-
11m
l,vv-
300m
l,pvr-nil
pf-23m
l,m
f-
18m
l,vv-245m
l
pf-21m
l,m
f-
17m
l,vv-245m
l
pf-10,m
f-
6m
l,vv180m
l,pvr-
60m
l
yes,11m
onths
10
chittibabu
50
52816
prox.penile
1.5
traum
a
c
IU
E-coli 
N
G
pf-6m
l,m
f-
3.3m
l,vv-215m
l,
PF-25m
l,M
F-
18m
l,vv-
300m
l,pvr 5m
l
pf-23m
l,m
f-
18m
l,vv-245m
l
pf-24m
l,m
f-
18m
l,vv-
320m
l,pvr-nil
pf-10m
l,m
f-
7m
l,vv250m
l
yes,10m
onths
11
um
ashankar
35
53715
bulbar urethra
1.4
inflam
m
c
IU
N
G
E-coli
pf-7m
l,m
f-
3m
l,vv180m
l
PF-24m
l,M
F-
17m
l,vv-
320m
l,pvr-nil
pf-22m
l,m
f-
18m
l,vv-
230m
l,pvr 10m
l
pf-16m
l,m
f-
111m
l,vv-240m
l
pf-9m
l,m
f-
4m
l,vv165m
l,pvr-
70m
l
yes,7m
onths
12
dharm
alingam
47
53374
prox.penile
1
traum
a
c
IU
pseudom
onas
N
G
spc
PF-26m
l,M
F-
12m
l,vv-
300m
l,pvr 5m
l
pf-25m
l,m
f-
18m
l,vv-320m
l
pf-25m
l,m
f-
12m
l,vv-300m
l
pf-22m
l,m
f-
16m
l,vv320m
l,pv
r-nil
N
O
13
chithirai
52
8079
bulbar urethra
1
traum
a
c
IU
E-coli 
E-coli
pf-4m
l,m
f-3m
l,vv-
150m
l,pvr-160m
l
PF-22m
l,M
F-
15m
l,vv-
200m
l,pvr-5m
l
PF-20M
L,M
F-
15m
l,vv170m
l,pv
r-10m
l
pf-21m
l,m
f-
17m
l,vv-245m
l
pf-20m
l,m
f-
15m
l,vv180m
l,pv
r-10m
l
N
O
14
dilli
72
55544
bulbar urethra
1.3
iatrogenic
c
IU
N
G
pseudom
onas
pf-5m
l,m
f-
3.2m
l,vv170m
l,p
vr-130m
l
PF-26m
l,M
F-
10m
l,vv-
300m
l,pvr 5m
l
pf-24m
l,m
f-
17m
l,vv-230m
l
lost follow
 up
15
ponnusam
y
50
17930
bulbar
1
idiopathic
c
IU
N
G
E-coli
pf-9m
l,m
f-4m
l,vv-
150m
l
PF-25m
l,M
F-
11m
l,vv-
320m
l,pvr 5m
l
pf-16m
l,m
f-
18m
l,vv-245m
l
pf-10m
l,m
f-
7m
l,vv-167m
l,pvr-
100m
l
yes,9m
onths
16
tam
ilarasan
52
22989
bulbar
0.5
traum
a
c
IU
E-coli 
N
G
pf-7m
l,m
f-
3m
l,vv180m
l
PF-24m
l,M
F-
17m
l,vv-
320m
l,pvr-nil
pf-23m
l,m
f-
18m
l,vv-245m
l
pf-21m
l,m
f-
17m
l,vv-245m
l
pf-22m
l,m
f-
16m
l,vv320m
l,pv
r-nil
N
O
17
sekar
40
26021
bulbar
1.8
traum
a
c
IU
N
G
pseudom
onas
pf-5.6m
l,m
f-
2.7m
l,vv-360m
l
PF-18m
l,M
F-
13m
l,vv200m
l
pf-16m
l,m
f-
18m
l,vv-245m
l
pf-12m
l,m
f-
8m
l,vv-200m
l,pvr-
140m
l
yes,6m
onths
18
m
unusam
y
40
25655
bulbar
1.5
idiopathic
c
IU
N
G
E-coli
spc
PF-20m
l,M
F-
14m
l,vv-
160m
l,pvr-10m
l
PF-19M
L,M
F-
14M
L,vv-
230m
l,pvr-5m
l
PF-15M
L,M
F-
10M
L,VV-240m
l,
PF-12M
L,M
F-
9M
L,VV210M
L,P
vr-70m
l
yes,8m
onths
19
pannerselvam
65
28435
bulbar
1
idiopathic
c
IU
pseudom
onas
N
G
pf-4m
l,m
f-3m
l,vv-
150m
l,pvr-160m
l
pF-22m
l,M
F-
17m
l,vv300m
l,pv
r-10m
l
PF-20M
L,M
F-
15m
l,vv170m
l,pv
r-10m
l
pf-21m
l,m
f-
17m
l,vv-245m
l
PF-19M
L,M
F-
15M
L,VV-
230M
L,PVR-N
il
N
O
20
rosario
51
2935
prox.penile
1
traum
a
c
IU
N
G
pseudom
onas
Pf-3.5m
l,M
F-
2m
l,vv-210m
l
pF-23m
l,M
F-
17m
l,vv-280m
l
PF-19M
L-M
F-
11M
L,VV-
230M
L,PVR-
PF-18M
L,M
F-
14M
L,VV-210M
L
Pf-17m
l,m
f-
14m
l,vv-200m
l 
,pvr-5m
l
N
O
21
David
60
3917
bulbar
1.5
traum
a
c
IU
proteus
N
G
spc
PF-19M
L,M
F-
14M
L,VV-200M
L
pf-16m
l,m
f-
12m
l,vv-245m
l
pf-10m
l,m
f-
7m
l,vv-167m
l,pvr-
100m
l
yes,6m
onths
22
m
elvin jothi
33
5711
bulbar
1.2
traum
a
c
IU
N
G
N
G
PF-10M
L,M
F-
6M
L,VV-170M
L
PF-21M
L,M
F-
17M
L,VV-165M
L,
PF-21M
L,M
F-
14m
l,vv160m
l,pv
r-10m
l
pf-19m
l.m
f-
15m
l,vv-
200m
l,pvr-5m
l
pf-18m
l,m
f-
14m
l,vv-200m
l 
,pvr-5m
l
N
O
23
Sivalingam
40
6211
bulbar
1
unknow
n
c
IU
N
G
E-coli
pf-6m
l,m
f-
4m
l,vv152m
l,pvr
100m
l
pF-23m
l,M
F-
17m
l,vv-280m
l
PF-21M
L,M
F-
14m
l,vv160m
l,pv
r-10m
l
pf-17m
l.m
f-
13m
l,vv-
200m
l,pvr-6m
l
PF-10M
L,M
F-
8M
L,VV165M
L,P
VR-70M
L
yes,
24
Ravi
40
7064
bulbar
1.2
iatrogenic
c
IU
E-coli 
N
G
pf-8m
l,m
f-4m
l,vv-
150m
l
pF-22m
l,M
F-
17m
l,vv200m
l,pv
r-10m
l
PF-17M
L,M
F-
12M
L,VV-210M
L
lost follow
 up
25
sathish kum
ar
26
26140
bulbar
1
inflam
m
c
IU+Triam
cin
N
G
N
G
pf-4.7m
l,M
F-
2.2M
L,VV-240
PF-
23.9M
L,9.6M
L,25
0M
L
PF-21M
L,M
F-
14m
l,vv160m
l,pv
r-10m
l
PF-21m
l,m
f-
11m
l,vv-245m
l
PF-20M
L,m
f-
10m
l,vv180m
l,pv
r-10m
l
N
O
26
Parthiban
28
32948
bulbar
1
traum
a
D
IU+Triam
cin
proteus
N
G
spc
PF-23M
L,M
F-
12M
L,VV-210M
L
PF-20M
L,M
F-
14m
l,vv160m
l,pv
r-10m
l
Pf-20m
l.m
f-
10m
l,vv-
200m
l,pvr-6m
l
PF-19M
L,M
F-
15M
L,VV-
230M
L,PVR-N
il
N
O
27
shankaran
25
34852
Bulbar
0.8
traum
a
D
IU+Triam
cin
N
G
N
G
spc
PF-24M
L,M
F-
12M
L,VV-175M
L
PF-19M
L,M
F-
9M
L,vv-
230m
l,pvr-5m
l
PF-19M
L.m
f-
10m
l,vv-
200m
l,pvr-5m
l
PF-17M
L,M
f-
10m
l,vv-200m
l 
,pvr-5m
l
N
O
28
rajasekar
53
34890
m
id penile urethra
1.1
idiopathic
D
IU+Triam
cin
N
G
E-coli
spc
PF-20M
L,M
F-
10M
L,VV-180M
L
PF-19M
L,M
F-
9M
L,vv-
230m
l,pvr-5m
l
PF-20M
L,M
F-
9.2M
L,VV-190M
L
PF-8m
l,M
F-
4m
l,vv180m
l,
yes,9m
onths
29
M
urugan
65
46586
bulbar
1.3
traum
a
D
IU+Triam
cin
N
G
N
G
PF-4M
L,M
F-
2.5M
L,VV-
180M
L,PVR-
PF-21M
L,M
F-
13M
L,VV-190M
L
PF-20M
L,M
F-
11M
L,VV-200M
L
PF 18M
L,M
F-
9M
L,VV-
235M
L,PVR-5M
L
PF-19M
L,M
F-
15M
L,VV-
230M
L,PVR-N
il
N
O
30
Guruvappa
53
44026
bulbar
1
inflam
m
D
IU+Triam
cin
pseudom
onas
N
G
PF-10M
L,M
F-
6M
L,VV-170M
L
PF-24M
L,M
F-
12M
L,VV-175M
L
PF-22M
L,M
F-
12m
l,vv-234m
l
PF-20M
L,M
F-
9.2M
L,VV-190M
L
PF-20M
L,M
F-
12m
l,vv-210m
l
no
31
ism
ail
55
7732
bulbar
1.2
idiopathic
D
IU+Triam
cin
E-coli 
N
G
pf-6m
l,m
f-3m
l,vv-
150m
l
PF-20M
L,M
F-
14M
L,VV-200M
L
PF- 18M
LM
L,M
F-
8M
L,VV-
230M
L,PVR 
PF-16M
L,M
F-
9M
L,VV-178M
L
PF-12M
L,M
F-
9.5M
L,VV210M
L,
Pvr-70m
l
yes,11m
onths
32
Jayaram
an
60
8833
bulbar
1
traum
a
D
IU+Triam
cin
N
G
N
G
PF-10M
L,M
F-
6M
L,VV-170M
L
pf-23m
l,M
F-
10M
L,VV-210M
L
PF-21M
L,M
F-
11m
l,vv160m
l,pv
r-10m
l
PF-20M
L.M
F-
11M
L,VV-230M
L
PF-19M
L,M
F-
9M
L,VV-
230M
L,PVR-N
il
N
O
33
dharm
alingam
47
9386
m
id penile
0.5
iatrogenic
D
IU+Triam
cin
N
G
N
G
pf-6m
l,m
f-3m
l,vv-
150m
l
PF-25M
L,M
F-
9M
L,vv-170m
l
pf-23m
l,m
f-
11m
l,vv-245m
l
pf-21m
l,m
f-
9m
l,vv-200m
l,pvr-
5m
l
pf-20m
l,m
f-
9.5m
l,vv-190m
l
N
O
34
pandiyan
45
9418
bulbar
1
idiopathic
D
IU+Triam
cin
N
G
N
G
pf-6m
l,m
f-
3.2m
l,vv-170m
l
pf-22m
l,m
f-
10m
l,vv-200m
l
pf-21m
l,m
f-
9m
l,vv-190m
l
PF-20M
L,M
F-
9.2M
L,VV-190M
L
pf-18m
l,m
f-
10m
l,vv-200m
l 
,pvr-5m
l
N
O
35
devaraj
40
9796
bulbar
1.2
traum
a
D
IU+Triam
cin
E-coli 
N
G
spc
pf-19m
l,M
F-
9M
L,VV-200M
L
pf-19m
l,m
f-
8m
l,vv-175m
l,pvr-
5m
l
pf-18M
L,M
F-
9.3M
L,VV-210M
L
pf-19m
l,m
f-
8m
l,vv-180m
l
N
O
36
kum
ar
43
12333
bulbar
1.5
inflam
m
D
IU+Triam
cin
N
G
N
G
pf-5m
l,m
f-
3.2m
l,vv160m
l,p
vr-100m
l
pf-21m
l,m
f-
10m
l,vv-240m
l
pf-21.5m
l,m
f-
9.2m
l,vv-195m
l
pf-21m
l,m
f-
9m
l,vv-200m
l,pvr-
5m
l
lost follow
 up
37
arum
ugam
47
12399
bulbar
0.8
idiopathic.
D
IU+Triam
cin
N
G
E-coli
PF-10M
L,M
F-
6M
L,VV-170M
L
pf-24m
l,m
f-
9m
l,vv-210m
l
pf-23m
l,m
f-
9m
l,vv-230m
l
pf-21m
l,m
f-
9m
l,vv-190m
l,pvr-
5m
l
N
O
38
kum
ar
32
16260
bulbar
1.5
idiopathic
D
IU+Triam
cin
N
G
pseudom
onas
spc
pf-19m
l,m
f-
9.8m
l,vv-256m
l
pf-18m
l,m
f-
8m
l,vv-215m
l,pvr-
5m
l
pf-18m
l,m
f-
8m
l,vv-200m
l,pvr-
140m
l
pf-9m
l,m
f-
4m
l,vv165m
l,pvr-
70m
l
yes,10 m
onths
39
santhanam
24
16636
bulbar
1.3
traum
a
D
IU+Triam
cin
N
G
N
G
pf-5.5m
l,m
f-
4.2m
l,vv-
165m
l,pvr-80m
l
pf-24.5m
l,m
f-
12m
l,vv-200m
l
pf-23m
l,m
f-
10m
l,vv-210m
l
pf-21.5m
l,m
f-
9m
l,vv-235m
l
pf-20m
l,m
f-
9m
l,vv-235m
l,pvr-
nil
N
O
40
senthil kum
ar
37
17023
bulbar
1
inflam
m
D
IU+Triam
cin
N
G
N
G
pf-7m
l,m
f-
3m
l,vv180m
l
pf-21.5m
l,m
f-
10m
l,vv-
235m
l,pvr-nil
PF-21M
L,M
F-
11m
l,vv160m
l,pv
r-10m
l
pf-23m
l,m
f-
11m
l,vv-175m
l
pf-20m
l,m
f-
9.3m
l,vv-210m
l
N
O
41
kannaiyan
38
17743
bulbar
0.9
traum
a
D
IU+Triam
cin
klebsiella
N
G
pf-5m
l,m
f-4m
l,vv-
165m
l,pvr-90m
l
pf-23m
l,m
f-
9m
l,vv-250m
l
pf-21m
l,m
f-
9.5m
l,vv-
235m
l,pvr-nil
pf-22m
l.m
f-
10m
l,vv-
200m
l,pvr-6m
l
pf-19m
l,m
f-
8m
l,vv-180m
l
N
O
42
am
ul raj
48
20804
m
id penile
1.5
inflam
m
D
IU+Triam
cin
N
G
N
G
not voided
pf-27m
l,m
f-
10m
l,vv-290m
l
pf-25m
l,m
f-
11m
l,vv-320m
l
pf-23m
l,m
f-
11m
l,vv-175m
l
pf-21m
l,m
f-
9m
l,vv-190m
l,pvr-
5m
l
N
O
43
karthikan
23
19567
bulbar
1
idiopathic
D
IU+Triam
cin
E-coli 
N
G
pf-5m
l,m
f-
3.2m
l,vv-
150m
l,pvr 90m
l
pf-20m
l,m
f-
9m
l,vv-235m
l
pf-17m
l,M
F-
9M
L,VV-210M
L
pf-16m
l,m
f-
10m
l,vv-
195m
lpvr-10m
l
PF-12M
L,M
F-
9M
L,VV210M
L,P
vr-70m
l
yes,10m
onths
44
sabastin
43
2186
bulbar
1.2
traum
a
D
IU+Triam
cin
N
G
E-coli
pf-9m
l,m
f-4m
l,vv-
150m
l
pf-24m
l,m
f-
9.8m
l,vv-240m
l
pf-22m
l,m
f-
10m
l,vv-245m
l
pf-23m
l,m
f-
11m
l,vv-175m
l
pf-21m
l,m
f-
9m
l,vv-190m
l,pvr-
5m
l
N
O
45
appan raj
33
26353
penile
0.9
idiopathic
D
IU+Triam
cin
N
G
N
G
pf-7m
l,m
f-
3m
l,vv180m
l
PF-26m
l,M
F-
18m
l,vv-
300m
l,pvr 5m
l
pf-24m
l,m
f-
12m
l,vv-230m
l
pf-22m
l,m
f-
9m
l,vv-235m
l
pf-20m
l,m
f-
10m
l,vv-
190m
l,pvr-nil
N
O
46
elum
alai
27
28752
bulbar
1
traum
a
D
IU+Triam
cin
N
G
N
G
pf-4m
l,m
f-3m
l,vv-
150m
l,pvr-160m
l
pf-24m
l,m
f-
11m
l,vv-258m
l
pf-23m
l,m
f-
11m
l,vv-245m
l
PF-20M
L,M
F-
9.2M
L,VV-190M
L
PF-19M
L,M
F-
9M
L,VV-
230M
L,PVR-N
il
N
O
47
kasi
35
24007
bulbar
0.7
inflam
m
D
IU+Triam
cin
N
G
N
G
spc
pf-22m
l,m
f-
9m
l,vv-232m
l
PF-21M
L,M
F-
11m
l,vv160m
l,pv
r-10m
l
lost follow
 up
48
Parthiban
28
28007
bulbar
1
idiopathic
D
IU+Triam
cin
E-coli 
N
G
pf-5m
l,m
f-3m
l,vv-
175,pvr-100m
l
pf-24m
l,m
f-
9.5m
l,vv-180
pf-22m
l,m
f-
9m
l,vv-175
PF-20M
L,M
F-
9.2M
L,VV-190M
L
pf-19m
l,m
f-
89m
l,vv-200m
l
N
O
49
dillibabu
49
26290
bulbar
0.5
traum
a
D
IU+Triam
cin
N
G
N
G
spc
pf-23m
l,m
f-
9m
l,vv-250m
l
pf-21m
l,m
f-
10m
l,vv-230m
l
PF-20M
L,M
F-
9.2M
L,VV-190M
L
pf-20m
l,m
f-
9m
l,vv-235m
l,pvr-
nil
N
O
50
saravanan
48
32064
bulbar
1.2
idiopathic
D
IU+Triam
cin
N
G
E-coli
pf-6m
l,m
f-
4m
l,vv152m
l,pvr
100m
l
pf-24m
l,m
f-
10m
l,vv-315m
l,
pf-23m
l,m
f-
12m
l,vv-215m
l
PF-16m
l,m
f-
11m
l,vv-245m
l
pf-12m
l,m
f-
7m
l,vv-165m
l,pvr-
90m
l
yes,8m
onths
